Heidi Overton's role in Trump's ibogaine policy

White House adviser shapes ibogaine policy

Heidi Overton, a senior health-policy adviser within the Trump administration, has been central to the development of ibogaine policy, a psychedelic substance under study for treating addiction and trauma. Her role has sparked significant internal debate, according to a report by The Atlantic.

What the report reveals

The report details how Joe Rogan, a prominent podcaster, approached President Donald Trump in April to discuss ibogaine's potential therapeutic benefits. Trump responded positively, leading to the drafting of an executive order on psychedelic therapies. However, the process became contentious when Overton, tasked with revising the draft, faced pushback from Rogan and other advocates who felt she was undermining Trump's intentions.

Overton's influence and controversies

Overton, described as a powerful yet low-profile figure in Trump's health policy team, has been accused by some of stalling initiatives aligned with the "Make America Healthy Again" (MAHA) movement. Critics argue she has slowed marijuana rescheduling and other reforms, while supporters claim she ensures policies are legally sound and aligned with Trump's goals.

Why it matters

Overton's handling of the ibogaine policy highlights the broader tensions within the Trump administration regarding health policy reforms. The debates around her role underscore the challenges of balancing rapid policy changes with the need for thorough review and consensus-building.

Overton's potential nomination as FDA commissioner could further amplify these discussions, as her approach to health policy continues to shape the administration's agenda.